Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Inhibitor TherapeuticsINTI EV-to-OCF is -4.15 as of Aug. 01, 2026. The stock has 1 warning sign investors should review. Among 1,410 Biotechnology companies, Inhibitor Therapeutics ranks better than 54.11% on this metric.
EV-to-OCF is calculated as enterprise value divided by its cash flow from operations. As of today, Inhibitor Therapeutics's Enterprise Value is $12.57 Mil.
Inhibitor Therapeutics's Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2026 was $-3.03 Mil. Therefore, Inhibitor Therapeutics's EV-to-OCF for today is -4.15.
The historical rank and industry rank for Inhibitor Therapeutics's EV-to-OCF or its related term are showing as below:
INTI'
s EV-to-OCF Range Over the Past 10 Years
Min: -4.53 Med: 0 Max: -4.15
Current: -4.15
During the past 13 years, the highest EV-to-OCF of Inhibitor Therapeutics was -4.15. The lowest was -4.53. And the median was .
INTI's EV-to-OCF is ranked better than 54.11% of 1410
companies
in the Biotechnology industry
Industry Median: -3.345
vs INTI: -4.15
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Inhibitor Therapeutics's PE Ratio (TTM) for today is calculated as:
Inhibitor Therapeutics's share price for today is $0.08.
Inhibitor Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.010.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Inhibitor Therapeutics's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Inhibitor Therapeutics EV-to-OCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Inhibitor Therapeutics's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where Inhibitor Therapeutics's EV-to-OCF falls into.
Inhibitor Therapeutics's current Enterprise Value is $12.57 Mil.
Inhibitor Therapeutics's Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-3.03 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Inhibitor Therapeutics (INTI) has a EV-to-OCF of -4.15 as of Aug. 01, 2026. According to the industry distribution chart, Inhibitor Therapeutics ranks #647 out of 1410 companies in the Biotechnology industry, placing it in the top 45.9%.
Is Inhibitor Therapeutics' EV-to-OCF too high?
Inhibitor Therapeutics' current EV-to-OCF is -4.15. Based on the distribution chart, Inhibitor Therapeutics ranks #647 out of 1410 companies in the Biotechnology industry, which is above the industry midpoint.
How does Inhibitor Therapeutics' EV-to-OCF compare to TPST and AKTX?
According to the Biotechnology industry distribution chart, Inhibitor Therapeutics ranks #647 out of 1410 companies for EV-to-OCF. This puts Inhibitor Therapeutics in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Biotechnology company?
A good EV-to-OCF depends on the Biotechnology industry context. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. Inhibitor Therapeutics's current EV-to-OCF is -4.15. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Inhibitor Therapeutics stock overvalued right now?
Inhibitor Therapeutics (INTI) has a current EV-to-OCF of -4.15. The current EV-to-OCF is -4.15. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For Inhibitor Therapeutics (INTI), the current EV-to-OCF is -4.15 as of Aug. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Inhibitor Therapeutics Inc is a pharmaceutical development company focused on developing and potentially commercializing therapeutics based on already approved active pharmaceutical ingredients, with a primary focus on basal cell carcinoma nevus syndrome (BCCNS), also known as Gorlin Syndrome. The Company develops therapeutics with patent-protected methods of use or delivery for certain cancers and non-cancerous proliferation disorders, and focuses on therapies for basal cell carcinoma (BCC) in the United States, utilizing itraconazole, an FDA-approved drug for fungal infections, with developed intellectual property and know-how related to the treatment of cancer patients using itraconazole.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
INTI has been successfully added to your 
